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Background: Active surveillance (AS) is a safe treatment strategy for men with
low-risk prostate cancer (PC) when performed in a research setting using strict
follow-up. However, less is known about the protocol adherence and outcomes for
AS in real-world practice.
Objective: To evaluate Prostate Cancer Research International Active Surveillance
(PRIAS) protocol adherence in a real-world cohort and to relate follow-up intensity
to oncological safety.
Design, setting, and participants: Patientswith biopsy-detected PC diagnosed from
2008 to 2014 treated with AS at six teaching hospitals in The Netherlands.
Intervention: AS included regular prostate-specific antigen (PSA) testing (every
3–6 mo) combined with a confirmatory biopsy 1 yr after diagnosis and every 3 yr
thereafter.
Outcome measurements and statistical analysis: The proportions of patients com-
plying with the PRIAS biopsy and PSA monitoring protocol were determined. We
assessed if PRIAS-discordant follow-up was associated with a higher risk of
metastasis compared with PRIAS-concordant follow-up using Cox regression
analysis. Analysis was performed for separate risk groups (PRIAS-eligible and
PRIAS-ineligible) on the basis of the PRIAS inclusion criteria.
Results and limitations: Of all patients on AS for >6 mo, 706/958 (74%) had PRIAS-
concordant PSAmonitoring. Overall concordant follow-up (PSA and repeat biopsy)
was observed in 415/958 patients (43%). The percentage of patients with overall
concordant follow-up varied between hospitals (range 34–60%; p < 0.001). Among
PRIAS-ineligible patients, PRIAS-discordant PSA monitoring was associated with a
higher risk of developing PC metastases during AS compared with patients with
concordant follow-up (hazard ratio 5.25, 95% confidence interval 1.02–27.1). In the
PRIAS-eligible population, we found no significant differences regarding rates of
metastases between patients with discordant and concordant follow-up.
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1. Introduction
The principle of active surveillance (AS) is to avoid
overtreatment of clinically insignificant prostate cancer
(PC) and to defer treatment until objective evidence of
disease progression [1]. Favorable AS outcomes in a trial
setting have led to its widespread acceptance [2–4]. How-
ever, the challenge remains to identify men with indolent
disease among those with progressive PC at risk of missing
the window of curability.
The protocols of published AS studies adhere to the same
principles: repeat prostate biopsies (intensity varying per
protocol, from yearly to every 3–4 yr) combined with
regular prostate-specific antigen (PSA) testing every 3–
6 mo [5]. However, these monitoring protocols are time-
consuming and therefore expensive. Moreover, repeat
biopsies are unpleasant for the patient and bear a risk of
bleeding and infection. It is therefore conceivable that AS
protocols are not followed as strictly in daily practice as is
recommended by the prevailing guidelines. This hypothesis
is supported by an inventory of real-world practice patterns
in the USA, which revealed that <13% of PC patients
undergo repeat biopsy beyond the first two years of AS
[6]. Furthermore, a survey among European urologists
indicated that 47% of those practicing AS do not use an
official AS protocol or are not involved in a clinical AS trial
[7]. A nationwide survey in Japan also showed that only
40.6% of the urologists surveyed performed a scheduled
repeat biopsy at 1 yr after AS initiation [8]. The possible
consequences of these AS protocol deviationswith regard to
oncological safety are for the most part unknown. This calls
for research assessing the safety of lower-intensity AS
monitoring.
In the present study, we evaluated AS follow-up
strategies for PC in six large Dutch teaching hospitals
covering up to 15% of PC patients in the Netherlands. We
determined the proportions of patients who undergo
follow-up testing according to the Dutch guidelines, which
are based on the follow-up protocol of the Prostate Cancer
International Active Surveillance (PRIAS) study [9]. Further-
more,we assessed if patientswith low-intensitymonitoring
had a higher risk of missing the window of curability
because of the development of metastatic PC during AS.
2. Patients and methods
2.1. Study setting and data collection
This study was conducted within the Santeon consortium, which
consists of seven large nonacademic teaching hospitals in the
Netherlands. During the study period, data for the AS cohorts from
six of these seven hospitals were available. The study focuses on the
same cohort of PC patients on AS diagnosed between January 1, 2008 and
December 31, 2014 on which we reported previously [10].
Data collection and analysis included initial age and tumor
characteristics at diagnosis, dates of follow-up serum PSA tests, repeat
biopsies, magnetic resonance imaging (MRI) of the prostate, and
metastasis rates [11].
2.2. Variation in follow-up strategy and compliance with PRIAS
The Dutch PC guidelines recommend that AS follow-up should be in
accordance with the protocol as described in PRIAS [12]. This includes a
PSA test every 3 mo in the first 2 yr, and every 6 mo thereafter. Scheduled
repeat biopsies should be performed at 1, 4, 7, and 10 yr following
diagnosis.
Definitions used for follow-up compliance with the PRIAS protocol
were comparable to those published by the PRIAS study group [13]. PSA
follow-up was regarded as concordant if a patient had undergone 75%
of the recommended number of PSA tests for their follow-up duration.
For example, a patient with an AS duration of 14 mo should have
undergone three or more PSA tests to be regarded as compliant.
To assess compliance with repeat biopsy testing, we evaluated the
percentage of patients who underwent the first (1 yr), second (4 yr), and
third biopsy (7 yr) among menwith follow-up of>1.5,>4.5, and>7.5 yr,
respectively. We also determined the percentage of patients who
received all scheduled biopsies according to the protocol, taking AS
duration into account. Follow-up was scored as discordant if a patient
should have undergone one or more biopsies according to the follow-up
scheme, but missed one or more. A separate analysis was performed to
determine in how many cases MRI of the prostate were performed
instead of a prostate biopsy. Protocol adherent follow-upwas assessed in
patients with an AS duration of >6 mo.
We assessed whether discordant follow-up was associated with a
higher rate of metastasis during AS follow-up using risk classification
based on the PRIAS inclusion criteria: PSA 10 ng/ml, PSA density
<0.2 ng/ml/ml, Gleason 6, fewer than three positive biopsy cores,
and clinical stage T2 [9]. Patients were classified as PRIAS-eligible
if they met all these criteria at baseline, and PRIAS-ineligible if they
did not.
Conclusions: We observed substantial variation in AS follow-up intensity be-
tween large urological practices in the Netherlands. Overall, 43% of patients on
AS in daily clinical practice receive PRIAS-concordant follow-up. Noncompli-
ance with the PRIAS follow-up protocol was associated with a higher rate of
metastasis among PRIAS-ineligible patients, indicating that strict protocol
adherence is important when these patients opt for AS.
Patient summary: Fewer than half of patients with prostate cancer on active
surveillance are monitored according to the follow-up protocol of the largest
ongoing active surveillance study. Lower-intensity monitoring may be less safe
for patients who are not in the lowest risk group.
© 2019 EuropeanAssociation of Urology. Published by Elsevier B.V. All rights reserved.
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2.3. Outcome measures
Our primary outcomemeasurewas the total percentages of patients who
received PSA monitoring, repeat biopsy testing, and overall follow-up
(PSA and biopsies combined) concordant with the PRIAS follow-up
protocol. Differences between hospitals in the proportion of patients
with concordant follow-up were determined. A secondary outcome
measure was the rate of metastasis (bone and/or lymph node) during AS
monitoring. A patient was considered to have developed metastatic PC
during AS follow-up (time between the date of diagnosis and
discontinuation of AS) if metastases were detected via diagnostic
imaging (MRI, choline or prostate-specific membrane antigen positron
emission tomography/computed tomography for lymph nodemetastasis
and/or visceral metastasis and a bone scan for bonemetastasis) or lymph
node metastasis found via lymph node dissection.
2.4. Statistical analysis
Possible significant differences in mean values between hospitals were
assessed using one-way analysis of variance. We evaluated differences in
the proportion of patients using Fisher’s exact test. Hazard ratios (HRs)
and 95% confidence intervals (CIs) were calculated using univariable Cox
regression. Analysis was performed using SPSS for Windows v.24.0 (IBM
Corp, Armonk, NY, USA). A p value of <0.05 was considered significant.
3. Results
3.1. Study population
A total of 1181 patients were diagnosed with PC and
enrolled in AS between January 1, 2008 and December
31, 2014 at six Santeon hospitals. This included an initial
181/1181 patients (15%) with incidental tumors (cT1a/b),
who were later excluded. Baseline characteristics for the
1000 patients with screen-detected PC on AS are presented
in Table 1. The table shows differences between hospitals
with regard to baseline serum PSA, PSA density, number of
positive biopsy cores, and proportions of PRIAS-eligible and
PRIAS-ineligible patients.
3.2. PSA follow-up testing
A total of 958 patients had treatment-free follow-up of
more than 6 mo. The percentages of patients receiving
PRIAS-concordant and -discordant PSA testing are pre-
sented in Fig. 1. The variation between hospitals was
considerable. Hospital 1 had the highest compliance, as 83%
of patients had PRIAS-concordant PSAmonitoring. The least
strict monitoring occurred in hospital 4, where only 55% of
the patients has PRIAS-concordant PSAmonitoring. Overall,
706/958 patients (74%) had PRIAS-concordant PSA moni-
toring. The proportion of patients with a PSA doubling time
(PSADT) of <3 yr did not differ significantly between the
groups with discordant and concordant PSA follow-up (42%
vs 48%; p = 0.156). The group of patients with discordant
PSA testing was slightly younger (mean age 66.8 vs 68.7 yr;
p < 0.001).
3.3. Repeat biopsies and overall PRIAS-concordant follow-up
Protocol adherence regarding scheduled prostate biopsies
also differed between hospitals. As can be seen in Fig. 2, the
highest percentage of patient compliance with the first
Table 1 – Baseline characteristics of the active surveillance patient population by hospitala
Hospital 1 Hospital 2 Hospital 3 Hospital 4 Hospital 5 Hospital 6 p value
Patients (n) 248 144 166 178 78 186
Age (yr) 67.9  6.4 67.3  6.5 68.1  6.6 67.4  5.6 67.6  5.7 65.3  6.8 <0.001
PSA (ng/ml) 8.2  5.4 7.4  3.4 7.0  3.3 9.2  4.8 8.2  4.1 8.6  4.9 <0.001
PSAD (ng/ml/ml) 0.17  0.14 0.18  0.11 0.14  0.07 0.21  0.12 0.19  0.11 0.18  0.12 <0.001
cT stage, n (%)b
T1c 200 (81) 110 (76) 104 (63) 144 (81) 74 (95) 156 (84)
T2a 11 (4) 10 (7) 25 (15) 8 (5) 1 (1) 9 (5)
T2b 2 (1) 1 (1) 4 (2) 7 (4) 0 (0) 0 (0)
T2c 4 (2) 3 (2) 0 (0) 4 (2) 0 (0) 4 (2)
T2 24 (10) 19 (12) 31 (19) 15 (8) 3 (3) 16 (9)
T3/T4 7 (3) 1 (1) 2 (1) 0 (0) 0 (0) 1 (1)
Total biopsy cores (n) 9.4  2.1 9.5 1.7 8.9  2.2 8.7  2.4 9.9  0.7 8.1 1.2 <0.001
Positive cores (n) 1.8  1.1 1.6  1.0 1.6  0.9 1.8  1.2 1.6  1.1 1.4  0.8 <0.001
GS, n (%)
4 0 (0) 3 (2) 0 (0) 0 (0) 0 (0) 2 (1)
5 0 (0) 5 (4) 0 (0) 0 (0) 2 (3) 3 (2)
6 230 (93) 136 (83) 165 (99) 171 (96) 74 (95) 169 (91)
3 + 4 15 (6) 10 (6) 1 (1) 6 (3) 2 (3) 12 (7)
4 + 3 3 (1) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0)
Risk group, n (%)c
PRIAS-eligible 123 (50) 85 (59) 104 (63) 60 (34) 36 (46) 102 (55)
PRIAS-ineligible 125 (50) 59 (41) 62 (37) 118 (66) 42 (54) 84 (45)
PSA = prostate-specific antigen; PSAD = PSA density (PSA/prostate volume measured via transrectal ultrasound or magnetic resonance imaging); GS = Gleason
sum score at diagnosis
a Results for continuous variables are reported as mean  standard deviation.
b Clinical T stage based on digital rectal examination and transrectal ultrasonography
c Risk classification based on PRIAS. PRIAS-eligible: PSA 10 ng/ml, PSAD <0.2 ng/ml/ml, GS 6, <3 positive biopsy cores, and cT stage T2; PRIAS-ineligible: not
complying with one or more of the PRIAS inclusion criteria listed for eligibility.
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scheduled repeat biopsy was in hospital 2 (79%), while the
lowest was in hospital 1 (48%). In the overall population,
473/912 patients (52%) were compliant with all scheduled
repeat biopsies during their follow-up. At an institutional
level, the highest percentage was found in hospital 2 (68%)
and the lowest in hospital 1 (40%).
There was also great variation between hospitals in the
percentage of patients with overall PRIAS-concordant
follow-up; hospital 4 had the lowest proportion of patients
with overall concordant follow-up (34%) and hospital 2 had
the highest (60%; Fig. 3).
3.4. MRI for follow-up
MRI of the prostatewas performed during follow-up in 449/
1000 patients (45%). The proportion of patients undergoing
prostate MRI during AS varied significantly among institu-
tions. The highest percentage was observed in hospital
6 (104/186, 56%) and the lowest in hospital 5 (22/78, 28%;
p < 0.001). In some cases, MRI was performed instead of
repeat biopsy. In a total of 41 patients, MRI of the prostate
was performed instead of the first repeat biopsy. If we
consider patients as compliant if MRI was performed
instead of the scheduled biopsy, the total number of
patients with PRIAS-concordant repeat biopsy (or MRI)
follow-up would increase from 473/912 (52%) to 537/912
(59%). Prostate MRI increasingly replaced prostate biopsies
over time. Of all patients diagnosed in 2008, 2/90 (2%)
underwent MRI instead of the first repeat biopsy. Among
patients diagnosed in 2014, this was performed in 15/126
cases (12%).
3.5. Follow-up intensity and oncological outcome
A total of 13 patients developed metastatic PC (positive
lymph nodes and/or bonemetastasis) while on AS, and thus
missed the window of curability during monitoring. The
median duration of AS was 40.8 mo (interquartile range
16.8–59.1). The baseline characteristics for these patients
are presented in Table 2.
To evaluate the potential association between follow-up
intensity and unfavorable oncological outcomes, data for
men who developed metastatic PC during AS follow-up
were analyzed. The rate of metastasis was significantly
higher among men who had low-intensity PSA monitoring
(<75% of recommended; Table 3). In the PRIAS-ineligible
risk group, the HR for developing metastasis during AS was
significantly higher among patients with discordant PSA
monitoring than the concordant PSA monitoring group (HR
5.3, 95% CI 1.02–27.10).
We found no significant correlation between discordant
biopsy testing and the rate of metastasis for both the PRIAS-
eligible and PRIAS-ineligible subgroups (p = 0.6). However,
among all the patients with discordant biopsy testing, 35%
had rapidly increasing PSA levels (defined as PSADT <3 yr),
which is significantly lower than for the concordant biopsy
group (54%; p < 0.001).
In the PRIAS-ineligible group, overall discordant follow-
up (discordant PSA monitoring and/or discordant biopsy
testing) was also associated with a higher rate of metastatic
PC (2% vs 0%; p = 0.047).
4. Discussion
In this study, we observed significant variation in AS
protocol adherence between six large teaching hospitals in
[(Fig._3)TD$FIG]
Fig. 3 – Percentages of patients with overall PRIAS-concordant follow-
up (concordant PSA monitoring and biopsy testing).
[(Fig._1)TD$FIG]
Fig. 1 – Percentage of patients with PRIAS concordant PSA testing. For
PRIAS-concordant testing, patients underwent 75% of the
recommended PSA tests, according to AS duration. For PRIAS-discordant
testing, patients underwent <75% of the total PSA tests recommended
by the PRIAS protocol.
[(Fig._2)TD$FIG]
Fig. 2 – Percentage of patients with PRIAS-concordant follow-up
biopsies. RB 1 = first repeat biopsy at 1 yr after diagnosis;
Overall = compliant with all scheduled biopsies according to AS
duration.
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the Netherlands. In the overall population, 43% of the
patients on AS received follow-up concordant with PRIAS.
These are important findings, as they confirm our hypothe-
sis that AS follow-up is less strict in daily clinical practice.
Results from a large number of prospective AS cohorts
have been published in the literature [12,14–21]. However,
results for compliance rates with the respective follow-up
protocols are limited. We identified two other study groups
that performed comparable research. Our findings are in
line with their results, as Luckenbaugh et al. [22] also
observed limited protocol adherence in a real-world cohort
treated with AS at collaborating urological practices in
Michigan (MUSIC). The authors reported that 26.5% of the
patients who remained on AS for a minimum of 2 yr had
follow-up compliant with the National Comprehensive
Cancer Network guidelines [22]. The PRIAS study group
reported that 91% of patients complied with all PSA visits
and 81% compliedwith the 1-yr prostate biopsy [16]. Overall
percentages in our cohort were lower, as we observed that
74% of patients (706/958) had concordant PSA testing and
63% (570/912) complied with the first repeat biopsy. The
differences between the PRIAS cohort and the real-world
populations described in the present study and the MUSIC
study indicate that there is a substantial gap regarding
AS protocol adherence between the research setting and
daily practice. The size of this gap may also differ at an
institutional level, as significant differences between
institutions were observed in both studies.
Table 3 – Risk of metastasis for low-intensity monitoring by risk group
FU Patients who developed mPC during AS, n/N (%) p valuea HR (95% CI)
PSA
PRIAS-eligible (n = 495) Discordant PSA monitoring 2/104 (2) 0.611 2.39 (0.42–13.50)
Concordant PSA monitoringb 4/391 (1)
PRIAS-ineligible (n = 463) Discordant PSA monitoring 5/148 (3) 0.037 5.25 (1.02–27.1)
Concordant PSA monitoring 2/315 (1)
Biopsy
PRIAS-eligible (n = 481) Discordant RB testingc 2/210 (1)
Concordant RB testen 4/271 (2) 0.701 0.36 (0.06–2.08)
PRIAS-ineligible (n = 431) Discordant RB testing 3/229 (1)
Concordant RB testen 4/202 (2) 0.711 0.32 (0.07–1.51)
Overall
PRIAS-eligible (n = 495) Overall discordant FU 2/257 (1) 0.434 0.30 (0.05–1.69)
Overall concordant FUd 4/238 (2)
PRIAS-ineligible (n = 463) Overall discordant FU 7/286 (2) 0.047 32.9 (0.02–51163.29)
Overall concordant FU 0/177 (0)
AS = active surveillance; mPC = metastatic prostate cancer; RB = repeat biopsy; FU = follow-up; HR = hazard ratio; CI = confidence interval.
a Fisher’s exact test.
b Patients underwent 75% of recommended PSA tests according to the PRIAS protocol for their AS duration.
c Patients underwent all scheduled RBs for their AS duration.
d Patients underwent PRIAS-concordant PSA monitoring and RB testing.
Table 2 – Patients who developed metastatic prostate cancer during AS FU
H No cT PSA (ng/ml) Pos. cores (n) GG Risk groupa PRIAS eligible PSADT (yr) Locationb AS FU (mo) PRIAS-C
PSA RB
1 626 T2 23.0 1 1 High No 3.4 LN 26 No No
912 T2 11.4 7 2 Intm. No 1.4 LN 19 Yes No
2 1192 T2 7.4 2 1 Low Yes 0.9 Bone 13 Yes Yes
1241 T1c 6.3 1 1 Low Yes 9.3 LN 84 Yes Yes
3 1881 T1c 9.0 1 1 Low No 4.6 Bone 49 No Yes
4 1497 T1c 16.0 1 1 Intm. No 0.3 LN 25 No Yes
1508 T2b 5.9 2 1 Low Yes 1.9 Bone, LN 39 No No
1577 T1c 17.0 1 1 Intm. No 0.9 Bone, LN 11 No Yes
5 2280 T1c 10.0 3 1 Low No 1.3 LN 13 No Yes
2284 T1c 5.8 1 1 Low Yes 1.2 LN 7 Yes Yes
2330 T1c 4.9 1 1 Low Yes 1.1 LN 4 Yes Yes
2573 T1c 7.0 1 1 Low No 7.5 Bone 73 Yes No
6 2843 T2 7.0 1 1 Low Yes 2.1 LN 24 No No
AS = active surveillance; H = hospital; PSA = prostate-specific antigen; Pos. = positive; GG = grade group; Intm. = intermediate; PSADT = PSA doubling time;
LN = lymph node; FU = follow-up; PRIAS-C = PRIAS-compliant; RB = repeat biopsy.
a Risk group classification (modified D’Amico) based on the following parameters. Low risk: PSA 10 ng/ml and Gleason 6 and cT stage T2; intermediate risk:
PSA 10–20 ng/ml and/or Gleason >6 and cT stage T2; high risk: PSA >20 ng/ml and/or Gleason >7 and/or cT stage >T2.
b Location where metastatic prostate cancer was found (no distinction between distant and local LNs).
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Noncompliance with AS protocols is understandable, as
patients consider repeat biopsies painful [13]. Moreover,
biopsies are associated with several complications such as
pain, hematuria, urinary tract infections, and even urosepsis
[23]. Given the significant burden, costs, and time
associated with frequent monitoring, we have to deliberate
on the intensity of AS follow-up schedules. However, it
remains challenging to determine for whom and to what
extent the intensity of AS follow-up schedules can be
reduced. Given the higher risk of missing the window of
curability, low-intensity monitoring may not be a safe
option for PRIAS-ineligible patients. However, we found no
significant difference in the rate of metastasis between
discordant and concordantmonitoring in the PRIAS-eligible
group. This suggests that patientswho can be classifiedwith
the lowest risk at diagnosis might be candidates for a less
intensive follow-up schedule without being at risk of
worsening of their prognosis.
We did not observe a higher rate of metastasis among
patients noncompliant with the PRIAS repeat biopsy
schedule in comparison to compliant patients. The lack of
association between biopsy noncompliance and prognosis
can be partly explained by the fact that most of these men
did not have rapidly increasing PSA (65% had a PSADT of
>3 yr). Of the patients who were compliant, 54% had a
PSADT of <3 yr, indicating that repeat biopsies were
performed more frequently in cases with faster rising
PSA. This indicates that the decision to repeat prostate
biopsy was partly based on serial serum PSA results instead
of the protocol advised. This can be further explained by
taking hospital 1 as an example. Hospital 1 had the lowest
percentage of patients complying with 1-yr repeat biopsy
(48%) but the highest percentage of patients with concor-
dant PSA monitoring (83%). The rate of metastasis was
relatively low in this hospital (2/248, 1%) in comparison to
the other clinics. These findings suggest that deviating from
the repeat biopsy protocol may be safe as long as PSA
kinetics are monitored closely.
The strengths of our study include the large sample size,
a study population representing the real-world clinical
situation, and evaluation of AS management strategies
including a wide range of follow-up tests. Besides the
strengths of the study, some limitations should be
acknowledged. First, the retrospective nature of the study
is a limitation and carries a risk of bias due to confounding
by indication, especially concerning allocation of patients to
a low- or high-intensity monitoring strategy. However,
given the fact that it is possible that patients with more
aggressive tumors received closer monitoring than patients
with less aggressive tumors, we still found significant
differences regarding rates of metastasis. Thus, this form of
bias has not altered our conclusions. Second, we only
evaluated whether AS follow-up was concordant with the
PRIAS follow-up guidelines. We did not evaluate deviations
from the PRIAS protocol regarding recommendations for
discontinuation of AS (ie, Gleason sum score 7 on repeat
biopsy or >2 cores positive). Therefore, we cannot assess
the potential impact of this on our observed outcomes, as
we do not know which patients remained on AS despite
Gleason upgrading or a substantial increase in tumor
volume. However, we did collect data for an individual’s PSA
course, which also provides important information on
tumor aggressiveness.
5. Conclusions
Compliance with an AS protocol in a real-world cohort is
low: 43% of patients on AS in daily clinical practice receive
PRIAS-concordant follow-up (52% comply with the biopsy
schedule and 74% with the PSA schedule). Compliance rates
vary substantially between hospitals, indicating a need for a
better understanding of outcomes among patients receiving
PRIAS-concordant and PRIAS-discordant follow-up. Non-
compliance with the PRIAS follow-up protocol was associ-
ated with a higher rate of metastasis among PRIAS-
ineligible patients. Higher rates of metastasis were found
for discordant PSA monitoring, but not among patients not
complying with the biopsy schedule, suggesting that PSA
compliance ismore important, since lowbiopsy compliance
seemed to be “compensated” by high PSA compliance. The
fact that discordant follow-up was not associated with a
higher rate of metastasis among PRIAS-eligible patients
suggests that less strict monitoring may be safe in this
subgroup. This information is vital in our journey towards a
more individualized approach for AS follow-up intensity
depending on the patient’s preferences and baseline tumor
characteristics.
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